Jazz Climbs After Judge Sides with Company in Patent Case

Jazz Pharmaceuticals Plc climbed to its highest value ever after winning a federal judge’s support in a patent dispute over its best-selling medicine Xyrem to treat narcolepsy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.